SEC Company Response from Viking Therapeutics, Inc. (VKTX) (CIK 0001607678) (VKTX) — Jul 17, 2018
Viking Therapeutics, Inc. (VKTX) (CIK 0001607678)
Date: July 17, 2018 · CIK: 0001607678 · Accession: 0001564590-18-016919
AI Filing Summary & Sentiment
File numbers found in text: 333-226133
Letter
vktx-corresp.DOCX.htm
12340 El Camino Real, Suite 250
San Diego, CA 92130
July 17, 2018
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Healthcare & Insurance
Attention: Abigail Jacobs or Erin Jaskot
100 F Street, N.E.
Washington, D.C. 20549
Re:
Viking Therapeutics, Inc.
Registration Statement on Form S-3
Filed July 11, 2018
File No. 333-226133
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Viking Therapeutics, Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the Registration Statement on Form S-3 (File No. 333-226133) of the Registrant (the “Registration Statement”), filed with the Securities and Exchange Commission (the “Commission”) on July 11, 2018, be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time, on July 19, 2018 or as soon thereafter as may be practicable. As of the date hereof, there is no managing or principal underwriter for any of the Registrant’s securities that may be offered pursuant to the Registration Statement. Future managing or principal underwriters, if any, will be identified in a prospectus supplement to the Registration Statement at the time of offering.
The Registrant hereby confirms that it is aware of its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed offering of the securities specified in the Registration Statement.
It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Jeffrey T. Hartlin of Paul Hastings LLP, by telephone at (650) 320-1804 or by email at jeffhartlin@paulhastings.com. The Registrant hereby authorizes Mr. Hartlin to orally modify or withdraw this request for acceleration.
Sincerely,
VIKING THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm vktx-corresp.DOCX.htm 12340 El Camino Real, Suite 250 San Diego, CA 92130 July 17, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance Attention: Abigail Jacobs or Erin Jaskot 100 F Street, N.E. Washington, D.C. 20549 Re: Viking Therapeutics, Inc. Registration Statement on Form S-3 Filed July 11, 2018 File No. 333-226133 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Viking Therapeutics, Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the Registration Statement on Form S-3 (File No. 333-226133) of the Registrant (the “Registration Statement”), filed with the Securities and Exchange Commission (the “Commission”) on July 11, 2018, be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time, on July 19, 2018 or as soon thereafter as may be practicable. As of the date hereof, there is no managing or principal underwriter for any of the Registrant’s securities that may be offered pursuant to the Registration Statement. Future managing or principal underwriters, if any, will be identified in a prospectus supplement to the Registration Statement at the time of offering. The Registrant hereby confirms that it is aware of its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed offering of the securities specified in the Registration Statement. It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Jeffrey T. Hartlin of Paul Hastings LLP, by telephone at (650) 320-1804 or by email at jeffhartlin@paulhastings.com. The Registrant hereby authorizes Mr. Hartlin to orally modify or withdraw this request for acceleration. Sincerely, VIKING THERAPEUTICS, INC. By: /s/ Brian Lian, Ph.D. Brian Lian, Ph.D. President and Chief Executive Officer cc:Jeffrey T. Hartlin, Esq. (Paul Hastings LLP)